Use filters to refine the search results.
|2017||Access to high cost cancer medicines through the lens of an Australian Senate Inquiry - defining the 'goods' at stake.||Ghinea, N; Little, M; Lipworth, W|
|2017||Caution needed in introduction of provisional approvals for medicines||Pace, J; Ghinea, N; Kerridge, I; Lipworth, W|
|Sep-2018||An ethical framework for the creation, governance and evaluation of accelerated access programs||Pace, J; Ghinea, N; Kerridge, I; Lipworth, W|
|Jan-2019||Clarifying the relationship between serious ethical violations and conflicts of interest||Lipworth, W; Ghinea, N; Kerridge, I|
|29-Jan-2019||Limiting religious contributions – a response to Schuklenk||Wiersma, M; Ghinea, N; Lipworth, W|
|2018||Clearing the air: towards agreement about access to high cost cancer medicines||Lipworth, W; Ghinea, N; Kerridge, I; Zalcberg, J|
|2018||“Treat them into the grave”: cancer physicians’ attitudes towards the use of high cost cancer medicines at the end of life||Wiersma, M; Ghinea, N; Kerridge, I; Lipworth, W|